Ajanta Pharma Limited Announces Unaudited Standalone and Consolidated Earnings Results for Third Quarter and Nine Months Ended December 31, 2017
January 25, 2018 at 02:37 pm IST
Share
Ajanta Pharma Limited announced unaudited standalone and consolidated earnings results for third quarter and nine months ended December 31, 2017. For the quarter, the company reported standalone total income from operations was INR 6,022 million against INR 5,523 million a year ago. Profit before tax was INR 1,975.3 million against INR 1,810.5 million a year ago. Profit for the period was INR 1,474.7 million against INR 1,426 million a year ago. Basic and diluted per share was INR 16.75 against INR 16.2 a year ago.
For the period, the company reported standalone total income from operations was INR 16,206.4 million against INR 15,463 million a year ago. Profit before tax was INR 4,945.3 million against INR 5,041.9 million a year ago. Profit for the period was INR 3,741.5 million against INR 3,928.1 million a year ago. Basic and diluted per share was INR 42.5 against INR 44.63 a year ago.
For the quarter, the company reported consolidated total income from operations were INR 5,654.7 million against INR 5,596.8 million a year ago. Profit before tax was INR 2,038.3 million against INR 2,112.6 million a year ago. Profit for the period was INR 187 million against INR 194.2 million a year ago.
For the period, the company reported consolidated total income from operations were INR 14,371.1 million against INR 14,638 million a year ago. Profit before tax was INR 4,570 million against INR 5,110.1 million a year ago. Profit for the period was INR 396.5 million against INR 445.2 million a year ago.
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
AJANTA PHARMA LIMITED 
